Platelet aggregation, but clopidogrel COX Inhibitors not inhibit cyclooxygenase. If the inhibition of cyclooxygenase leads to negative effects on kidney function and sodium retention and the lung, neuroendocrine, arterioles and veins should function, then it in a clinical difference between aspirin and clopidogrel lead. The most important result is the overall mortality T, hospitalization for heart failure, stroke, and The quality of life T as secondary Re endpoints. Trials of AF atrial fibrillation and heart failure are closely related conditions. Perhaps half of the H In studies of patients with AF have some form of heart failure, although many reports give enough attention to the diagnosis. While there is much evidence that a heart failure increased HTES risk in patients with chronic AF, gives the inverse far from certain, even as new start-AF, in patients with heart insufficiency associated with a worse prognosis, probably because it both a marker and cause of worsening heart failure. In studies with AF, patients with heart failure Similar rates of systemic emboli to other patients and the reduction rate with anticoagulation is also Similar. Compared with placebo or no antiplatelet therapy, anticoagulants reduce the overall mortality T in patients with atrial fibrillation. W However, whereas systemic embolism tr Gt around 50% of all Todesf Lle or kardiovaskul R hospitalization in patients with atrial fibrillation receiving anticoagulant therapy, which no heart failure, tr Gt it about 15% only in patients with heart failure. Trials of AF largely ignored the results of the h Ufigsten severe patients, such as worsening heart failure and death. In a combined analysis of two large randomized studies, patients were en assigned to ximelagatran has a low rate of hospitalization for heart failure than those assigned to warfarin. Other new drugs are superior to warfarin in this regard awaits exploration. Aspirin is usually not to reduce thromboembolic events in patients with atrial fibrillation and warfarin was lower in patients with accompanying big ventricular en Re dysfunction or heart failure. Aspirin does not reduce mortality in these studies. Recent studies have shown that the combination of aspirin and clopidogrel is less than warfarin, but this combination is better than aspirin alone for patients with atrial fibrillation who do not f Rderf compatibility available were for the treatment with warfarin. However, clopidogrel alone is a better choice than to be in combination with aspirin. In summary, one can assume that these tests really were studies of heart failure in patients with atrial fibrillation to dispense with FA, which are used as surrogate markers of heart failure. If this is the case, k These tests nnte for detecting an effect of warfarin are interpreted in heart failure. Tive prophylaxis of thromboembolism from the heart Sen insufficiency is an hour INDICATIVE diagnosis in studies of prophylaxis with curves Sen thromboembolism in patients admitted to carried out the h Tal with an acute disease Medical. Prophylactic use of subcutaneous unfractionated heparin and low molecular weight heparin and fondaparinux reduced the rate of deep vein thrombosis, although no pulmonary embolism. M for may have increased, there is a HTES risk of bleeding with UFH be, but the efficiency is Similar to the agent. Patients with heart failure usually have fewer rats.